PMC:7324763 / 49883-50234 JSONTXT

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T811","span":{"begin":9,"end":16},"obj":"CHEBI:59132;CHEBI:59132"},{"id":"T812","span":{"begin":68,"end":75},"obj":"GO:0010467"},{"id":"T813","span":{"begin":242,"end":246},"obj":"PR:000001002"},{"id":"T98034","span":{"begin":9,"end":16},"obj":"CHEBI:59132;CHEBI:59132"},{"id":"T96260","span":{"begin":68,"end":75},"obj":"GO:0010467"},{"id":"T13912","span":{"begin":242,"end":246},"obj":"PR:000001002"}],"text":"Chimeric antigen receptor NK cells (CAR-NK cells) are engineered to express virtually any receptor(s) of interest and were originally designed to enhance the ability of NK cells to eliminate cancer cells via receptors targeting EGFR (163) or CD19 (164), which are present on many cancer types and B cell hematological malignancies, respectively (164)."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T610","span":{"begin":26,"end":34},"obj":"Body_part"},{"id":"T611","span":{"begin":29,"end":34},"obj":"Body_part"},{"id":"T612","span":{"begin":40,"end":48},"obj":"Body_part"},{"id":"T613","span":{"begin":43,"end":48},"obj":"Body_part"},{"id":"T614","span":{"begin":169,"end":177},"obj":"Body_part"},{"id":"T615","span":{"begin":172,"end":177},"obj":"Body_part"},{"id":"T616","span":{"begin":198,"end":203},"obj":"Body_part"},{"id":"T617","span":{"begin":299,"end":303},"obj":"Body_part"}],"attributes":[{"id":"A610","pred":"fma_id","subj":"T610","obj":"http://purl.org/sig/ont/fma/fma63147"},{"id":"A611","pred":"fma_id","subj":"T611","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A612","pred":"fma_id","subj":"T612","obj":"http://purl.org/sig/ont/fma/fma63147"},{"id":"A613","pred":"fma_id","subj":"T613","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A614","pred":"fma_id","subj":"T614","obj":"http://purl.org/sig/ont/fma/fma63147"},{"id":"A615","pred":"fma_id","subj":"T615","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A616","pred":"fma_id","subj":"T616","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A617","pred":"fma_id","subj":"T617","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Chimeric antigen receptor NK cells (CAR-NK cells) are engineered to express virtually any receptor(s) of interest and were originally designed to enhance the ability of NK cells to eliminate cancer cells via receptors targeting EGFR (163) or CD19 (164), which are present on many cancer types and B cell hematological malignancies, respectively (164)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T381","span":{"begin":191,"end":197},"obj":"Disease"},{"id":"T382","span":{"begin":280,"end":286},"obj":"Disease"}],"attributes":[{"id":"A381","pred":"mondo_id","subj":"T381","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A382","pred":"mondo_id","subj":"T382","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"}],"text":"Chimeric antigen receptor NK cells (CAR-NK cells) are engineered to express virtually any receptor(s) of interest and were originally designed to enhance the ability of NK cells to eliminate cancer cells via receptors targeting EGFR (163) or CD19 (164), which are present on many cancer types and B cell hematological malignancies, respectively (164)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T608","span":{"begin":26,"end":34},"obj":"http://purl.obolibrary.org/obo/CL_0000623"},{"id":"T609","span":{"begin":36,"end":39},"obj":"http://purl.obolibrary.org/obo/CLO_0002199"},{"id":"T610","span":{"begin":40,"end":48},"obj":"http://purl.obolibrary.org/obo/CL_0000623"},{"id":"T611","span":{"begin":169,"end":177},"obj":"http://purl.obolibrary.org/obo/CL_0000623"},{"id":"T612","span":{"begin":198,"end":203},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T613","span":{"begin":234,"end":237},"obj":"http://purl.obolibrary.org/obo/CLO_0001003"},{"id":"T614","span":{"begin":242,"end":246},"obj":"http://purl.obolibrary.org/obo/CLO_0053432"},{"id":"T615","span":{"begin":297,"end":303},"obj":"http://purl.obolibrary.org/obo/CL_0000236"}],"text":"Chimeric antigen receptor NK cells (CAR-NK cells) are engineered to express virtually any receptor(s) of interest and were originally designed to enhance the ability of NK cells to eliminate cancer cells via receptors targeting EGFR (163) or CD19 (164), which are present on many cancer types and B cell hematological malignancies, respectively (164)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T81162","span":{"begin":9,"end":16},"obj":"Chemical"}],"attributes":[{"id":"A16835","pred":"chebi_id","subj":"T81162","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"}],"text":"Chimeric antigen receptor NK cells (CAR-NK cells) are engineered to express virtually any receptor(s) of interest and were originally designed to enhance the ability of NK cells to eliminate cancer cells via receptors targeting EGFR (163) or CD19 (164), which are present on many cancer types and B cell hematological malignancies, respectively (164)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1450","span":{"begin":228,"end":232},"obj":"Gene"},{"id":"1459","span":{"begin":191,"end":197},"obj":"Disease"},{"id":"1460","span":{"begin":280,"end":286},"obj":"Disease"},{"id":"1461","span":{"begin":318,"end":330},"obj":"Disease"}],"attributes":[{"id":"A1450","pred":"tao:has_database_id","subj":"1450","obj":"Gene:1956"},{"id":"A1459","pred":"tao:has_database_id","subj":"1459","obj":"MESH:D009369"},{"id":"A1460","pred":"tao:has_database_id","subj":"1460","obj":"MESH:D009369"},{"id":"A1461","pred":"tao:has_database_id","subj":"1461","obj":"MESH:D009369"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Chimeric antigen receptor NK cells (CAR-NK cells) are engineered to express virtually any receptor(s) of interest and were originally designed to enhance the ability of NK cells to eliminate cancer cells via receptors targeting EGFR (163) or CD19 (164), which are present on many cancer types and B cell hematological malignancies, respectively (164)."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T74","span":{"begin":191,"end":197},"obj":"Phenotype"},{"id":"T75","span":{"begin":280,"end":286},"obj":"Phenotype"}],"attributes":[{"id":"A74","pred":"hp_id","subj":"T74","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A75","pred":"hp_id","subj":"T75","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Chimeric antigen receptor NK cells (CAR-NK cells) are engineered to express virtually any receptor(s) of interest and were originally designed to enhance the ability of NK cells to eliminate cancer cells via receptors targeting EGFR (163) or CD19 (164), which are present on many cancer types and B cell hematological malignancies, respectively (164)."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T139","span":{"begin":228,"end":232},"obj":"http://purl.obolibrary.org/obo/GO_0005006"}],"text":"Chimeric antigen receptor NK cells (CAR-NK cells) are engineered to express virtually any receptor(s) of interest and were originally designed to enhance the ability of NK cells to eliminate cancer cells via receptors targeting EGFR (163) or CD19 (164), which are present on many cancer types and B cell hematological malignancies, respectively (164)."}

{"project":"MyTest","denotations":[{"id":"32655581-26155832-34771748","span":{"begin":234,"end":237},"obj":"26155832"},{"id":"32655581-32023374-34771749","span":{"begin":248,"end":251},"obj":"32023374"},{"id":"32655581-32023374-34771750","span":{"begin":346,"end":349},"obj":"32023374"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Chimeric antigen receptor NK cells (CAR-NK cells) are engineered to express virtually any receptor(s) of interest and were originally designed to enhance the ability of NK cells to eliminate cancer cells via receptors targeting EGFR (163) or CD19 (164), which are present on many cancer types and B cell hematological malignancies, respectively (164)."}

{"project":"TEST0","denotations":[{"id":"32655581-234-241-3171321","span":{"begin":234,"end":237},"obj":"[\"26155832\"]"},{"id":"32655581-231-238-3171322","span":{"begin":248,"end":251},"obj":"[\"32023374\"]"},{"id":"32655581-232-239-3171323","span":{"begin":346,"end":349},"obj":"[\"32023374\"]"}],"text":"Chimeric antigen receptor NK cells (CAR-NK cells) are engineered to express virtually any receptor(s) of interest and were originally designed to enhance the ability of NK cells to eliminate cancer cells via receptors targeting EGFR (163) or CD19 (164), which are present on many cancer types and B cell hematological malignancies, respectively (164)."}

{"project":"2_test","denotations":[{"id":"32655581-26155832-34771748","span":{"begin":234,"end":237},"obj":"26155832"},{"id":"32655581-32023374-34771749","span":{"begin":248,"end":251},"obj":"32023374"},{"id":"32655581-32023374-34771750","span":{"begin":346,"end":349},"obj":"32023374"}],"text":"Chimeric antigen receptor NK cells (CAR-NK cells) are engineered to express virtually any receptor(s) of interest and were originally designed to enhance the ability of NK cells to eliminate cancer cells via receptors targeting EGFR (163) or CD19 (164), which are present on many cancer types and B cell hematological malignancies, respectively (164)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T315","span":{"begin":0,"end":351},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Chimeric antigen receptor NK cells (CAR-NK cells) are engineered to express virtually any receptor(s) of interest and were originally designed to enhance the ability of NK cells to eliminate cancer cells via receptors targeting EGFR (163) or CD19 (164), which are present on many cancer types and B cell hematological malignancies, respectively (164)."}